This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bagger, J. P. Articles by Jensen, B. S. Search for Related Content PubMed PubMed Citation Articles by Bagger, J. P. Articles by Jensen, B. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB VERAPAMIL HYDROCHLORIDE

(Circulation. 1997;95:411-414.)
© 1997 American Heart Association, Inc.

Articles

Effect of Verapamil in Intermittent Claudication

A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study After Individual Dose-Response Assessment

Jens Peder Bagger, MD; Per Helligsoe, MD; Flemming Randsbaek, MS; Hans Henrik Kimose, MD; Bent Skov Jensen, MD

the Vascular Surgery Unit and Cardiology Department (J.P.B.), Skejby Section, Aarhus University Hospital, Aarhus, Denmark.

Correspondence to Jens Peder Bagger, MD, Cardiological Sciences, St George's Hospital, London SW17 ORE.

Background The calcium antagonist verapamil is a vasodilator drug that has been shown to increase oxygen extraction of ischemic tissues in coronary and peripheral vascular disease.

Methods and Results Since the balance between the positive and the negative effects of vasodilation may be delicate in ischemic diseases a dose-response study (dose range, 120 to 480 mg) was established to determine optimal, individual dosages of slow-release verapamil in 44 patients with stable intermittent claudication (Fontaine classification stage II) with respect to walking capacity. A randomized, double-blind, placebo-controlled, cross-over study (4 weeks) was performed to assess clinical and hemodynamic effects of verapamil. The optimal daily dose of verapamil on maximal walking ability was 120 (8 patients), 240 (8 patients), 360 (14 patients), and 480 mg (14 patients). Walking distances were measured at a metronome-controlled speed of 60 steps per minute on level surface. Optimal individual doses of verapamil increased mean pain-free walking distance by 29% from 44.9 to 57.8 meters (P<.01) and maximal walking distance by 49% from 100.7 to 149.8 meters (P<.001) compared with placebo. The increase in maximal walking distance correlated positively only with initial systolic ankle pressure (r=.49, P<.001) and ankle/brachial pressure index (r=.37, P<.013). Verapamil had no effect on systolic ankle pressure, ankle/brachial pressure index, peripheral leg temperature, or blood pressure, which suggests that the drug may have extrahemodynamic effects, possibly brought about through improved oxygen metabolism.

Conclusions Verapamil showed significant clinical benefits in patients with moderate intermittent claudication in this short-term study. Individual optimization of drug dosage should be considered an option both in trials and in the clinical setting in these patients.

Key Words: calcium antagonists • vasodilation • claudication

This article has been cited by other articles:

				K. Casey, B. H. Tonnessen, W. C. Sternbergh III, and S. R. Money Medical Management of Intermittent Claudication Vascular and Endovascular Surgery, September 1, 2004; 38(5): 391 - 399. [Abstract] [PDF]

				S. M Dean Pharmacologic treatment for intermittent claudication Vascular Medicine, November 1, 2002; 7(4): 301 - 309. [Abstract] [PDF]

				M. R. Jaff Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options Angiology, November 1, 2002; 53(6): 627 - 633. [Abstract] [PDF]

				W. R. Hiatt Medical Treatment of Peripheral Arterial Disease and Claudication N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621. [Full Text] [PDF]

				M. Lievre, S. Morand, B. Besse, J.-N. Fiessinger, and J.-P. Boissel Oral Beraprost Sodium, a Prostaglandin I2 Analogue, for Intermittent Claudication : A Double-Blind, Randomized, Multicenter Controlled Trial Circulation, July 25, 2000; 102(4): 426 - 431. [Abstract] [Full Text] [PDF]

				A. J Maxwell, B. E Anderson, and J. P Cooke Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar(R) Vascular Medicine, February 1, 2000; 5(1): 11 - 19. [Abstract] [PDF]

				R. D. Feldman, N. Campbell, P. Larochelle, P. Bolli, E. D. Burgess, S. G. Carruthers, J. S. Floras, R. B. Haynes, G. Honos, F. H.H. Leenen, et al. 1999 Canadian recommendations for the management of hypertension Can. Med. Assoc. J., December 14, 1999; 161(90120): S1 - 17. [Abstract] [Full Text] [PDF]

				VERAPAMIL HELPFUL FOR INTERMITTENT CLAUDICATION Journal Watch (General), February 4, 1997; 1997(204): 4 - 4. [Full Text]